Albireo Pharma Inc.
https://www.albireopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Albireo Pharma Inc.
EMA Says Yes To Eight New Medicines, Holds Fire On Others
The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.
Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.
EU Decision Time For Albireo’s Rare Liver Disease Drug
Odevixibat, which could become the first drug approved for treating progressive familial intrahepatic cholestasis in children, is up for an opinion from the European Medicines Agency.
Albireo Sets Sights On Rare Disease Model
Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Albireo AB
- Biodel Inc.